Correction to: Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study, by Kim M, Kim TH, Shin DY, Lim DJ, Kim EY, Kim WB, Chung JH, Shong YK, Kim BH, and Kim WG on behalf of Korean Thyroid Cancer Study Group (KTCSG).; Thyroid 2018;28(3)340–348. DOI: 10.1089/thy.2017.0356

Thyroid, Volume 28, Issue 5, Page 686-686, May 2018.


https://ift.tt/2G62q9p